Focus 4: Emerging Pipeline and Portfolio Diversification (Gene Editing, etc.) Investors will watch for updates on non-GLP-1 assets, including oncology, gene therapies, and the recent up-to-$7 billion acquisition of Kelonia Therapeutics
Eligible North Miami patients may schedule telehealth consultations to discuss Tirzepatide treatment options with a licensed healthcare provider
Side Effects of Compounded Semaglutide While compounded semaglutide is highly effective, its important to be aware of potential side effects
Force Factor(R) Launches Super GLP-1(TM) Support Formulas at Food, Drug, and Mass retailers nationwide Featuring Eriomin(R) from Ingredients by Nature Ingredients by Nature's Eriomin Featured in New Force Factor Cardio-Metabolic Supplement Line MONTCLAIR, Calif., May 4, 2026 (Newswire.com) - Ingredients by Nature (IBN) today announced that its patented citrus bioflavonoid complex, Eriomin, will be featured in three new GLP-1-supporting dietary supplements from Force Factor